Jonathan S. Treisman
Expertise in
18
conditions

Dr. Jonathan S. Treisman

Hematology
7410 W Rawson Ave, 
Franklin, WI 
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
7410 W Rawson Ave, 
Franklin, WI 

Overview

Jonathan S. Treisman, MD, is a hematologist and oncologist at Ascension Wisconsin in Franklin, WI.Dr. Treisman is board-certified in Internal Medicine, Medical Oncology, and Hematology. He provides medical oncology and hematology specialty care to adults with cancer and disorders of the blood. Dr. Treisman has a special interest in patients with hematologic malignancies, genitourinary, lung, and colorectal cancers.

Dr. Treisman is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Follicular Lymphoma, Upper Tract Urothelial Carcinoma (UTUC), Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration.

Dr. Treisman is board certified in The American Board Of Internal Medicine - Medical Oncology and The American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 19 clinical trials. Dr. Treisman is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WI

Board Certifications

The American Board Of Internal Medicine - Medical Oncology
The American Board Of Internal Medicine - Internal Medicine

Fellowships

Fred Hutchinson Cancer Research Center
National Cancer Institute
National Institutes of Health
University of Washington Program

Hospital Affiliations

Ascension All Saints Hospital
Ascension Columbia St. Mary's Hospital Milwaukee
Ascension SE Wisconsin Hospital - Elmbrook Campus
Ascension SE Wisconsin Hospital - Franklin Campus
Ascension SE Wisconsin Hospital - St. Joseph Campus
Ascension St. Francis Hospital
Ascension Columbia St Marys Hospital Milwaukee
Aurora St Lukes Medical Center
Ascension All Saints Hospital
Ascension Se Wisconsin Hospital
Ascension St Francis Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Ascension Wisconsin Health Center - Rawson Avenue - Reiman Cancer Center
7410 W Rawson Ave, Franklin, WI 53132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
Journal: Clinical lung cancer
Published: November 08, 2022
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Froedtert And The Medical College Of Wisconsin Froedtert Hospital

9200 W Wisconsin Ave, 
Milwaukee, WI 
 (8.7 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Fenske is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. Fenske is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fenske is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Froedtert Hospital

900 N. 92nd St., 
Milwaukee, WI 
 (8.6 miles away)
414-805-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Joshua Field is an Associate Medical Director at the Versiti Blood Center of Wisconsin and an Assistant Professor of Medicine at the Medical College of Wisconsin. Dr. Field specializes in the treatment of sickle cell disease and other benign hematological disorders at Froedtert Hospital and Children’s Hospital of Wisconsin. Dr. Field graduated from the University of Iowa Medical School. He completed an Internal Medicine Residency and Fellowships in Hematology and Transfusion Medicine at Washington University in St. Louis, where he was Chief Resident in Internal Medicine and Chief Fellow in Hematology/Oncology. Dr. Field is Board Certified in Internal Medicine and Hematology. Dr. Field is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, Congenital Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Field is board certified in Hematology and Internal Medicine. Dr. Field is currently accepting new patients.

Expertise in
15
conditions
Dr. Anita B. D'souza
Hematology | Oncology
Expertise in
15
conditions
Dr. Anita B. D'souza
Hematology | Oncology
Referral may be required

Clinical Cancer Center - Froedtert Hospital

8800 W. Doyne Ave., 
Milwaukee, WI 
 (8.6 miles away)
414-805-0505
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Anita D’Souza is a professor of medicine (hematology/oncology). She completed her medical school from Goa Medical College, India where she graduated at the top of her class and was awarded Best Medical Graduate. She completed her internal medicine residency from William Beaumont Hospital in Michigan where she received the Zimmerman Award for Outstanding Clinical Judgment, Leadership, and Integrity. She completed her hematology/oncology fellowship from the Mayo Clinic in Rochester, Minnesota. She is a past recipient of the Daniel McCarty Award for Research Excellent and Women in Science Rising Pioneer Award at MCW. Dr. D'souza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. D'souza is board certified in Medical Oncology And Hematology and Internal Medicine. Dr. D'souza is currently accepting new patients.

Frequently Asked Questions about Dr. Jonathan S. Treisman

How do I make an appointment with Dr. Jonathan S. Treisman?

You can book an appointment with Dr. Jonathan S. Treisman by calling their office at 414-427-2360. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan S. Treisman a top-rated expert for Large-Cell Immunoblastic Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan S. Treisman is classified as an Distinguished expert for Large-Cell Immunoblastic Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan S. Treisman specialize in?

While Dr. Jonathan S. Treisman is a Hematology, they have specific expertise in Large-Cell Immunoblastic Lymphoma, Follicular Lymphoma, and Upper Tract Urothelial Carcinoma (UTUC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jonathan S. Treisman participate in research or clinical trials?

Yes. Dr. Jonathan S. Treisman has published 7 articles and abstracts on conditions like Large-Cell Immunoblastic Lymphoma. You can view a list of Dr. Jonathan S. Treisman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan S. Treisman accept my insurance?

Dr. Jonathan S. Treisman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 414-427-2360 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Treisman's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile